What is the average increase in blood glucose levels with Repatha (Evolocumab) in a typical adult patient with hypercholesterolemia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 28, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Blood Glucose Effects of Repatha (Evolocumab)

Repatha (evolocumab) does not increase blood glucose levels and has no clinically meaningful effect on glycemic control in patients with or without diabetes. 1, 2

Evidence from Major Clinical Trials

The most robust evidence comes from the FOURIER trial, which specifically analyzed glycemic effects in 27,564 patients over a median follow-up of 2.2 years. 1

Key Findings on Glucose Metabolism

  • HbA1c levels remained similar between evolocumab and placebo groups throughout the study period in patients with diabetes, prediabetes, and normoglycemia 1
  • Fasting plasma glucose (FPG) showed no differences between treatment groups over time across all glycemic categories 1
  • No increased risk of new-onset diabetes was observed (HR 1.05,95% CI 0.94-1.17) in patients without diabetes at baseline 1
  • In patients with prediabetes specifically, evolocumab showed no increased diabetes risk (HR 1.00,95% CI 0.89-1.13) 1

Additional Supporting Evidence

The BERSON trial (981 patients with type 2 diabetes) demonstrated that evolocumab combined with atorvastatin showed no clinically meaningful differences in changes over time in glycemic variables (fasting serum glucose and HbA1c) between evolocumab and placebo groups. 2

Clinical Implications

Evolocumab is safe for use in patients with diabetes or at risk for diabetes without concern for worsening glycemic control. 1, 2 This contrasts sharply with some other lipid-lowering agents:

  • Niacin significantly increases blood glucose, particularly at high doses, though modest doses (750-2,000 mg/day) cause only modest changes generally amenable to adjustment of diabetes therapy 3
  • Statins are associated with modestly increased risk of incident diabetes 4

Common Pitfalls to Avoid

  • Do not withhold evolocumab from diabetic patients due to glucose concerns—the evidence clearly shows no adverse glycemic effects 1, 2
  • Do not require more frequent glucose monitoring specifically because of evolocumab initiation, as it does not affect glucose metabolism 1
  • Evolocumab's cardiovascular benefits are consistent in patients with and without diabetes (HR 0.83 for primary endpoint in diabetics vs 0.87 in non-diabetics, p-interaction=0.60) 1

References

Related Questions

Can Mounjaro (tirzepatide) and Repatha (evolocumab) be administered on the same day in a patient with type 2 diabetes and high cholesterol, or should they be spaced out to minimize potential interactions?
Can Repatha (evolocumab) cause hypertriglyceridemia?
Does Repatha (evolocumab) increase blood glucose or worsen glycemic control in patients with diabetes or impaired glucose tolerance?
Do PCSK9 inhibitor antibodies (e.g., evolocumab, alirocumab) used for hypercholesterolemia cause rhabdomyolysis?
What is the recommended duration of evolocumab therapy?
Can angiotensin-converting enzyme (ACE) inhibitors help with orthostatic hypotension in patients with hypertension or heart failure?
What antidepressant would be recommended for a patient with treatment-resistant Major Depressive Disorder (MDD) and anxiety, who has previously failed Lexapro (escitalopram), Wellbutrin (bupropion), and Cymbalta (duloxetine)?
What are the management steps for a patient with hyponatremia after pituitary surgery, with a history of pituitary tumor and currently taking losartan (angiotensin II receptor antagonist)?
What is the differential diagnosis for a patient presenting with acute flaccid paralysis?
What is the recommended treatment for a patient suspected of having an Enterococcus faecalis infection, particularly in a healthcare setting or with a history that suggests increased susceptibility?
What does a basophil (white blood cell) count of 1.2% indicate?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.